Patients: 333 people aged between 16 and 65 years with schizophrenia (DSM-IV; mean age 40.8 years; 69% male) who discontinued treatment with the assigned atypical antipsychotic in the first phase of the study (for any reason). Exclusions: prior resistance to study drugs or treatment with clozapine for resistance; history of serious adverse reaction to study drugs; first episode schizophrenia; schizoaffective disorder; mental retardation; cognitive disorder; pregnant; breast feeding; or serious medical comorbidity.
Intervention: Olanzapine (7.5-30 mg/day); quetiapine (200-800 mg/day); risperidone (1.5-6 mg/day); or ziprasidone (40-160 mg/day). Participants were randomised to a different antipsychotic to the one they had previously discontinued.
Outcomes: Time until discontinuation of treatment for any reason.
Patient follow up: 98.5% of participants provided time to discontinuation data.
MAIN RESULTS
Time to discontinuation for any reason differed significantly between treatments (p = 0.004; see http://www.ebmentalhealth.com/supplemental for table 1). Discontinuation was significantly earlier with quetiapine and ziprasidone than with olanzapine or risperidone, but there was no significant difference in time to discontinuation between risperidone and olanzapine or ziprasidone and quetiapine (see http://www.ebmentalhealth.com/supplemental for table 2). Although there was a significant difference between treatments in time to discontinuation because of lack of efficacy overall (p,0.05), pairwise comparisons between treatments found no significant differences after corrections for multiple comparisons. There was no significant difference overall in time to discontinuation owing to adverse events.
CONCLUSIONS
Risperidone and olanzapine increase time to treatment discontinuation compared with quetiapine and ziprasidone in people with schizophrenia who have previously discontinued taking another atypical antipsychotic. Commentary F ifty years of antipsychotic drug treatment of people with schizophrenia have not provided sufficient data for evidence-based approaches to the challenges clinicians face everyday. Which drug is best for this patient, and at what dose? Should the dose be changed and, if so, in which direction? Should a switch to another drug be effected and, if so, to which one? Other than the modest superiority of clozapine in treatment resistant patients and the clarification of the optimal dose range with risperidone, clinical trials have not provided this vital information. Research to gain regulatory approval does not address these practical questions, and post-marketing research provides much data of the ''our drug is better'' variety, giving the clinician little help with these key decisions.
In this regard the CUTLASS and CATIE clinical trials are welcome. Dealing with patients representative of common practice and asking clinically relevant questions, these trials 1-3 have supported clozapine superiority while finding little or no evidence for differential efficacy and modest evidence for differential effectiveness among first and second generation antipsychotic (SGA) drugs. The current report by Stroup et al addresses switching between SGA drugs. Results support the feasibility of switching, but benefit is modest. Time remaining on drug favours olanzapine and risperidone over zaprasidone and quietiapine, but the latter two drugs may have been dosed too low-the problem of coming to market without determining optimal dose. The time remaining on olanzapine will be sharply reduced by increased awareness of the robust adverse effects on metabolism.
These new data are important, but do they guide evidence-based practice? The clinical trial creates a horse race. A clear winner on a key variable has implications for the individual patient. But when efficacy and effectiveness differences are modest and risk is not calculated, little guidance for clinical decisions is forthcoming. In this instance, note that all antipsychotic drugs impede dopamine signalling and have similar efficacy except for clozapine. Attention then turns to adverse effects and cost where there are substantial differences. The doctor treats an individual (not a cohort), so the task is to find the optimal risk/benefit ratio for each individual patient. It is here that general knowledge and clinical judgement are critical: dyskinesia-switch to a drug benign for TD; sexual side effects-select a compound which does not elevate prolactin; risk for cardiovascular disease and diabetes-select a compound to minimise adverse metabolic effects (and institute treatment aimed at lifestyle change).
In short, there are minimal therapeutic differences between the dopamine antagonists and substantial differences in adverse effect profiles. Doctors use this knowledge for clinical reasoning with individual patients, with little specific guidance from clinical trials.
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